Precision Medicine

A new report reveals a healthcare system at odds with modern life, driving women to skip care. But at-home tech and new information sources are forcing a change.

The spatial biology leader will unveil its roadmap at AGBT 2026, targeting the next frontiers of drug discovery with 3D imaging and human-relevant models.

WellAve Dermatology opens a Mohs surgery center in Easton, bringing a top-tier surgeon and gold-standard cancer care to a medically underserved region.

Clene Inc. faces investors with promising data for ALS and MS, but a looming cash crunch makes its upcoming conference a critical test of survival.

The mobile health firm now reaches 25 states with its tech-driven model, aiming to close care gaps and answer federal critics of in-home assessments.

With two blockbuster cancer drugs driving record revenue, all eyes are on Syndax's upcoming earnings call for its 2026 outlook and growth strategy.

New five-year data for SYFOVRE shows a significant delay in geographic atrophy progression, offering long-term hope but also sparking clinical debate.

With a major €12.5M EU funding package, Step Pharma is fast-tracking dencatistat, a novel therapy targeting a key vulnerability in ovarian and endometrial cancers.

With a pivotal data release on the horizon, Passage Bio heads to two major conferences. Can its dementia gene therapy program win over Wall Street?

Serina Therapeutics enrolls the first patient in a trial for SER-252, a novel Parkinson's therapy designed to improve symptoms without current side effects.

With major grants from top foundations, Lario Therapeutics expands its precision neuroscience platform, offering new hope for complex neurological disorders.

With major investor conferences ahead, Ceribell showcases impressive revenue growth fueled by its AI-driven EEG system and a string of new FDA clearances.

With impressive preliminary sales and key pipeline updates, Mirum Pharmaceuticals' upcoming earnings call will focus on its strategy for sustained growth in 2026.

After a major pipeline pivot, Keros Therapeutics faces investors with a new lead drug, a fortified balance sheet, and a high-stakes strategy to prove.

A landmark study finds nearly half of Americans use OTC drugs weekly, revealing a quiet revolution in self-care that challenges current healthcare policy.

New head-to-head study results for POSLUMA PET imaging could redefine diagnostic clarity for prostate cancer, promising earlier and more precise detection.

After two decades of global use, Fziomed's anti-adhesion gel has treated one million patients, signaling a major shift in post-surgical recovery.

New data on Spyre Therapeutics' SPY003 suggests a twice-yearly shot for IBD is possible, part of a broader strategy to challenge market giants.

A new biotech emerges with massive funding and a next-gen 'shuttle' to deliver safer, more effective Alzheimer's therapies directly to the brain.

The luxury gym now accepts pre-tax health funds for memberships, signaling a major shift where high-end fitness is becoming a form of prescribed medicine.